Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation

The multikinase inhibitor sorafenib is under clinical investigation for the treatment of many solid tumors, but in most cases, the molecular target responsible for the clinical effect is unknown. Furthermore, enhancing the effectiveness of sorafenib using combination strategies is a major clinical c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Cancer
Main Authors: Groenendijk, Floris H, Mellema, Wouter W, van der Burg, Eline, Schut, Eva, Hauptmann, Michael, Horlings, Hugo M, Willems, Stefan M, van den Heuvel, Michel M, Jonkers, Jos, Smit, Egbert F, Bernards, René
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2015
Assuntos:
Cancer Therapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4312923/
https://ncbi.nlm.nih.gov/pubmed/25080865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.29113
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados